SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Pablo Neruda

PatientPablo Neruda
Date of birth1959-07-12
IdentifiersMRN HR-ML051-SYN; SSN (made up) 000-51-2976
Document date2026-06-15
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review: biopsy and staging results; medical oncology seen today. [S]

History of Present Illness

Mr. Neruda returns two weeks after his first visit, with a professional Spanish interpreter. In the past ten days he had an MRI of the prostate, a targeted biopsy at the urology practice, a CT scan, a bone scan and a PSMA PET/CT. The results were explained to him this morning by Dr. Okonkwo-Lund of medical oncology and again today: prostate cancer, Gleason 4+4, that has spread to two lymph nodes in the pelvis and to two places in the bones, the right hip bone and the lowest lumbar vertebra, with nothing in the lungs, liver or other organs. He chose, after hearing the options, to start apalutamide today, with a leuprolide injection in one week and radiotherapy to the prostate in about six weeks. His blood was drawn today for germline genetic testing after counseling. He had his bone density scan this morning. The right hip pain is a little better on acetaminophen, 5 of 10 at worst, and still wakes him some nights; he has no leg weakness, numbness, or change in bladder or bowel control. His urinary symptoms are unchanged. He feels the news is hard but says he would rather know. He wants to keep writing every morning and to continue his duties. [S]

ElementDetail
DiagnosisProstate adenocarcinoma, Gleason 4+4 (Grade Group 4), 9 of 14 cores
StagingTwo pelvic lymph nodes and two bone metastases (right ilium, L5); no visceral disease: low volume
DecisionApalutamide from today, leuprolide in one week, radiotherapy to the prostate; no docetaxel
Starting todayApalutamide 240 mg daily; cholecalciferol 2000 units daily

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo weight loss, fever or night sweats
GenitourinaryPositiveFrequency, weak stream and nocturia three times, unchanged; no blood in the urine
MusculoskeletalPositiveRight hip and low back pain, 5 of 10 at worst on acetaminophen
NeurologicalNegativeNo leg weakness, numbness or saddle numbness; no change in bladder or bowel control
PsychiatricNegativeWorried but coping; PHQ-2 score 1

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-04-06 to 2026-07-13completedS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route2026-06-01 to 2026-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route2026-06-15activeS
Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route2026-06-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-15Body height178cmS
2026-06-15Body weight92kgS
2026-06-15Body mass index (BMI) [Ratio]29kg/m2S
2026-06-15Systolic blood pressure142mm[Hg]S
2026-06-15Diastolic blood pressure86mm[Hg]S
2026-06-15Heart rate74/minS
2026-06-15Respiratory rate14/minS
2026-06-15Body temperature36.6CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-15DXA Femur [T-score] Bone density-2.1{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2026-06-15DXA Lumbar spine [T-score] Bone density-1.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2026-06-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-06-15Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S

Physical Exam

Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; walks without help, favoring the right hip slightly
CardiovascularRegular rhythm; blood pressure 142/86 mm Hg; no ankle swelling
MusculoskeletalTender over the right iliac crest; no midline spinal tenderness
NeurologicalStrength 5 of 5 in both legs; sensation and knee and ankle reflexes normal

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA before treatmentBaseline, then every 3 to 6 months on androgen deprivationUp to date46.8 ng/mL at the first visit
LaboratoryTestosteroneBaseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL)Up to date468 ng/dL at the first visit
LaboratoryBlood count, chemistry, alkaline phosphatase and LDHBaseline in metastatic diseaseUp to dateHemoglobin 13.6 g/dL; creatinine 0.96 mg/dL; alkaline phosphatase 168 U/L (raised); LDH 208 U/L; calcium 9.6 mg/dL
LaboratoryTSH before apalutamideBaseline, then periodically on apalutamideOrderedOrdered today before the first dose
LaboratoryHemoglobin A1c and lipid panelBaseline and yearly on androgen deprivationUp to dateA1c 5.9 percent and LDL 140 mg/dL at the first visit
LaboratoryCalcium and 25-hydroxyvitamin DBaseline and periodically on androgen deprivation and bone-protective drugsUp to dateCalcium 9.6 mg/dL and vitamin D 22 ng/mL at the first visit; cholecalciferol starts today
ImagingBone density (DXA) with FRAXBaseline before androgen deprivation, then every 1 to 2 yearsCompleted todayFemoral neck T-score -2.1; L1 to L4 -1.4; FRAX hip 3.4 percent, major osteoporotic 13 percent
ImagingStaging: CT, bone scan and PSMA PET/CTAt diagnosisUp to dateCompleted in the past ten days; low volume on conventional imaging; PSMA PET/CT concordant
ExaminationBlood pressure and cardiovascular assessmentEvery visit on androgen deprivationCompleted today142/86 mm Hg; no chest pain or breathlessness
ExaminationNeurological check for spinal cord compressionEvery visit with spinal metastasesCompleted todayNormal leg strength, sensation and reflexes; no bladder or bowel change
SurveyDistress and depression screen (PHQ-2)At diagnosis and at intervalsCompleted todayPHQ-2 score 1
SurveyPain scoreEvery visit with symptomatic metastasesCompleted today5 of 10 at worst on acetaminophen, down from 6
SurveyUrinary symptoms (IPSS)Baseline before treatment, then every follow-up visitUp to dateIPSS 17 at the first visit; unchanged
SurveySexual functionBaseline before treatment and periodicallyCompleted todayReviewed before androgen deprivation; loss of libido and erections explained
SurveyCognitionPeriodically on androgen deprivationDueMini-Cog at the annual wellness visit
Medication safetyTestosterone flare protectionWhen starting a GnRH agonist with bone metastasesCompleted todayApalutamide starts today, one week before leuprolide
Medication safetyDrug interactions with apalutamideWhen starting and with any new medicineCompleted todayStrong CYP3A4 inducer: amlodipine levels expected to fall; blood pressure check in four weeks
Medication safetyFalls and fracture risk on apalutamideEvery visit on androgen deprivationCompleted todayNo falls; counseled on rugs, lighting and night-time walking
ReferralMedical oncology (genitourinary)Once, then through treatmentCompleted todaySeen today; recommendations in the consultation note
ReferralGermline genetic testing with counselingOnce, for metastatic diseaseCompleted todayCounseled and blood drawn today; result in two to three weeks
ReferralRadiation oncology for radiotherapy to the prostateOnceOrderedPlanning visit in about four weeks
Self-managementPhysical activity, calcium intake, no tobacco, and care in SpanishEvery visitCompleted todayWalking as pain allows; calcium from food; written plan in Spanish

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)

Follow-up: Leuprolide at the oncology clinic in one week. Dental examination before the next visit. Review in four weeks with PSA, testosterone, chemistry, vitamin D and blood pressure. Next scheduled visit 2026-07-13: four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan. [S]